Have a feature idea you'd love to see implemented?
Let us know!
SYRS Syros Pharmaceuticals Inc
Price (delayed)
$0.26
Market cap
$6.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.07
Enterprise value
$6.81M
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop
Highlights
SYRS's EPS is up by 29% since the previous quarter
SYRS's net income is up by 26% from the previous quarter and by 7% YoY
The equity has shrunk by 131% YoY and by 75% QoQ
SYRS's revenue has shrunk by 96% YoY and by 91% QoQ
Key stats
What are the main financial stats of SYRS
Market
Valuations
Earnings
Shares outstanding
26.83M
Market cap
$6.98M
Enterprise value
$6.81M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
26.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.64
Revenue
$386,000
EBIT
-$92.49M
EBITDA
-$91.14M
Free cash flow
-$98.37M
Per share
Balance sheet
Liquidity
EPS
-$3.07
Free cash flow per share
-$2.5
Book value per share
-$0.41
Revenue per share
$0.01
TBVPS
$2.16
Total assets
$85M
Total liabilities
$96.12M
Debt
$60.23M
Equity
-$11.12M
Working capital
$35.54M
Debt to equity
-5.41
Current ratio
2.25
Quick ratio
2.13
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
-23,611.4%
Gross margin
100%
Net margin
-25,340.7%
Operating margin
-28,927.2%
Return on assets
-79.1%
Return on equity
-2,746.8%
Return on invested capital
-151.9%
Return on capital employed
-163.4%
Return on sales
-23,959.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SYRS stock price
How has the Syros Pharmaceuticals stock price performed over time
Intraday
-10.34%
1 week
-5.49%
1 month
-88.39%
1 year
-91.03%
YTD
-96.66%
QTD
-87.91%
Financial performance
How have Syros Pharmaceuticals's revenue and profit performed over time
Revenue
$386,000
Gross profit
$386,000
Operating income
-$111.66M
Net income
-$97.82M
Gross margin
100%
Net margin
-25,340.7%
SYRS's revenue has shrunk by 96% YoY and by 91% QoQ
The gross profit has dropped by 96% year-on-year and by 91% since the previous quarter
SYRS's net income is up by 26% from the previous quarter and by 7% YoY
The company's operating income rose by 19% YoY and by 7% QoQ
Growth
What is Syros Pharmaceuticals's growth rate over time
Valuation
What is Syros Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
26.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.64
SYRS's EPS is up by 29% since the previous quarter
The equity has shrunk by 131% YoY and by 75% QoQ
SYRS's revenue has shrunk by 96% YoY and by 91% QoQ
The price to sales (P/S) is 67% lower than the last 4 quarters average of 80.0 and 32% lower than the 5-year quarterly average of 39.0
Efficiency
How efficient is Syros Pharmaceuticals business performance
SYRS's return on invested capital has dropped by 55% year-on-year but it is up by 24% since the previous quarter
SYRS's ROA is down by 47% YoY but it is up by 16% from the previous quarter
Dividends
What is SYRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SYRS.
Financial health
How did Syros Pharmaceuticals financials performed over time
The total assets is 12% less than the total liabilities
Syros Pharmaceuticals's quick ratio has decreased by 48% YoY and by 36% QoQ
The current ratio has declined by 48% year-on-year and by 35% since the previous quarter
The equity has shrunk by 131% YoY and by 75% QoQ
Syros Pharmaceuticals's debt to equity has increased by 43% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.